The (L-MIND) study evaluated Monjuvi + lenalidomide for r/r DLBCL. Tafasitamab is co-marketed by Incyte & MorphoSys under the brand name Monjuvi in the US while Minjuvi in the EU, the UK & Canada
At the data cutoff of Feb 2022, 34% had undergone treatment for 2yrs. with a median duration of therapy of 4.3yrs., 23 were alive & 13 remained on treatment, incl. 6 were on treatment for 5yrs., CR in 23 patients incl. 4 were refractory to their primary therapy, PR in 4 patients & 2 were still on treatment. The results will be presented at SOHO 2022
Patients experienced a lower frequency of all-grade & grade ≥3 AEs during monothx. The therapy was approved in the US in combination with lenalidomide for r/r DLBCL & has received CMA in the EU
Ref: MorphoSys | Image: MorphoSys
